Your browser doesn't support javascript.
loading
Fighting Enteroviral Infections to Prevent Type 1 Diabetes.
Nekoua, Magloire Pandoua; Mercier, Ambroise; Alhazmi, Abdulaziz; Sane, Famara; Alidjinou, Enagnon Kazali; Hober, Didier.
Afiliação
  • Nekoua MP; Laboratoire de Virologie ULR3610, Université de Lille, CHU Lille, 59000 Lille, France.
  • Mercier A; Laboratoire de Virologie ULR3610, Université de Lille, CHU Lille, 59000 Lille, France.
  • Alhazmi A; Laboratoire de Virologie ULR3610, Université de Lille, CHU Lille, 59000 Lille, France.
  • Sane F; Microbiology and Parasitology Department, College of Medicine, Jazan University, Jazan 82911, Saudi Arabia.
  • Alidjinou EK; Laboratoire de Virologie ULR3610, Université de Lille, CHU Lille, 59000 Lille, France.
  • Hober D; Laboratoire de Virologie ULR3610, Université de Lille, CHU Lille, 59000 Lille, France.
Microorganisms ; 10(4)2022 Apr 01.
Article em En | MEDLINE | ID: mdl-35456818
ABSTRACT
Enteroviruses (EVs), especially coxsackieviruses B (CVB), are believed to trigger or accelerate islet autoimmunity in genetically susceptible individuals that results in type 1 diabetes (T1D). Therefore, strategies are needed to fight against EV infections. There are no approved antiviral drugs currently available, but various antiviral drugs targeting viral or host cell proteins and vaccines have recently shown potential to combat CVB infections and may be used as new therapeutic strategies to prevent or reduce the risk of T1D and/or preserve ß-cell function among patients with islet autoantibodies or T1D.
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Ano de publicação: 2022 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Ano de publicação: 2022 Tipo de documento: Article